Candel Therapeutics Inc (CADL)
8.435
+0.46
(+5.70%)
USD |
NASDAQ |
May 02, 16:00
8.435
0.00 (0.00%)
After-Hours: 17:25
Candel Therapeutics Cash from Operations (TTM): -34.24M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -34.24M |
September 30, 2023 | -33.71M |
June 30, 2023 | -34.28M |
March 31, 2023 | -34.18M |
December 31, 2022 | -31.42M |
September 30, 2022 | -29.77M |
June 30, 2022 | -27.28M |
Date | Value |
---|---|
March 31, 2022 | -24.64M |
December 31, 2021 | -22.22M |
September 30, 2021 | -20.40M |
June 30, 2021 | -15.01M |
March 31, 2021 | -12.48M |
December 31, 2020 | -9.071M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-34.28M
Minimum
Jun 2023
-9.071M
Maximum
Dec 2020
-25.29M
Average
-27.28M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
Allurion Technologies Inc | -63.98M |
AngioDynamics Inc | -17.20M |
Eliem Therapeutics Inc | -20.60M |
Macrogenics Inc | -78.20M |
GlycoMimetics Inc | -34.88M |